| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1348731 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CDKN2B mRNA; more ... | CTD | PMID:17070097 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:731792 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CDKN2B mRNA | CTD | PMID:16611356 PMID:20805476 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1348731 | 6480464 | Tetrachlorodibenzodioxin affects the expression of CDKN2B mRNA | CTD | PMID:22298810 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:731792 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CDKN2B mRNA | CTD | PMID:19770486 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:731792 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CDKN2B mRNA | CTD | PMID:16611356 |
| 2-acetamidofluorene | increases expression | ISO | RGD:731792 | 6480464 | 2-Acetylaminofluorene results in increased expression of CDKN2B mRNA | CTD | PMID:17317680 |
| 4,4'-diaminodiphenylmethane | decreases expression | ISO | RGD:731792 | 6480464 | 4,4'-diaminodiphenylmethane results in decreased expression of CDKN2B mRNA | CTD | PMID:18648102 |
| 5-aza-2'-deoxycytidine | affects expression | ISO | RGD:1348731 | 6480464 | decitabine affects the expression of CDKN2B mRNA | CTD | PMID:16882708 |
| 5-aza-2'-deoxycytidine | increases expression | ISO | RGD:1348731 | 6480464 | decitabine results in increased expression of CDKN2B mRNA | CTD | PMID:17785578 PMID:17679729 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:1348731 | 6480464 | [decitabine affects the methylation of CDKN2B promoter] which affects the expression of CDKN2B mRNA | CTD | PMID:18704418 PMID:18704418 |
| 5-aza-2'-deoxycytidine | increases expression | ISO | RGD:1348731 | 6480464 | decitabine results in increased expression of CDKN2B mRNA | CTD | PMID:17679729 PMID:17785578 |
| 5-aza-2'-deoxycytidine | decreases methylation | ISO | RGD:1348731 | 6480464 | decitabine results in decreased methylation of CDKN2B gene | CTD | PMID:17294728 |
| 5-aza-2'-deoxycytidine | decreases methylation | ISO | RGD:1348731 | 6480464 | decitabine results in decreased methylation of CDKN2B promoter | CTD | PMID:19194470 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:1348731 | 6480464 | [decitabine affects the methylation of CDKN2B promoter] which affects the expression of CDKN2B mRNA | CTD | PMID:18704418 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:1348731 | 6480464 | decitabine promotes the reaction [trichostatin A results in increased expression of CDKN2B mRNA] | CTD | PMID:18718068 |
| 5-aza-2'-deoxycytidine | affects methylation | ISO | RGD:1348731 | 6480464 | decitabine affects the methylation of CDKN2B gene | CTD | PMID:17056112 |
| 5-aza-2'-deoxycytidine | affects expression | ISO | RGD:1348731 | 6480464 | decitabine affects the expression of CDKN2B protein | CTD | PMID:17056112 |
| 5-azacytidine | decreases methylation | ISO | RGD:1348731 | 6480464 | Azacitidine results in decreased methylation of CDKN2B promoter | CTD | PMID:19194470 |
| 5-azacytidine | multiple interactions | ISO | RGD:1348731 | 6480464 | [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B | CTD | PMID:19148494 |
| 5-azacytidine | affects response to substance | ISO | RGD:1348731 | 6480464 | CDKN2B promoter modified form affects the susceptibility to Azacitidine | CTD | PMID:17611569 |
| afimoxifene | multiple interactions | ISO | RGD:1348731 | 6480464 | 4-hydroxytamoxifen inhibits the reaction [Estrogens results in decreased expression of CDKN2B mRNA] | CTD | PMID:21233418 |
| aflatoxin B1 | affects expression | ISO | RGD:1348731 | 6480464 | Aflatoxin B1 affects the expression of CDKN2B protein | CTD | PMID:20106945 |
| aflatoxin B1 | increases expression | ISO | RGD:1348731 | 6480464 | Aflatoxin B1 results in increased expression of CDKN2B mRNA | CTD | PMID:21641981 |
| all-trans-retinoic acid | increases expression | ISO | RGD:1348731 | 6480464 | Tretinoin results in increased expression of CDKN2B mRNA | CTD | PMID:17138961 |
| all-trans-retinoic acid | increases expression | ISO | RGD:1348731 | 6480464 | Tretinoin results in increased expression of CDKN2B mRNA | CTD | PMID:21934132 PMID:17138961 |
| all-trans-retinoic acid | increases expression | ISO | RGD:1348731 | 6480464 | Tretinoin results in increased expression of CDKN2B mRNA | CTD | PMID:17138961 PMID:21934132 |
| ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of CDKN2B mRNA | CTD | PMID:16483693 |
| arsenic atom | decreases expression | ISO | RGD:1348731 | 6480464 | Arsenic results in decreased expression of CDKN2B mRNA | CTD | PMID:19945496 |
| benzene | multiple interactions | ISO | RGD:1348731 | 6480464 | [Benzene results in increased methylation of CDKN2B promoter] which results in decreased expression of CDKN2B mRNA | CTD | PMID:20044985 PMID:20044985 |
| benzene | multiple interactions | ISO | RGD:1348731 | 6480464 | [Benzene results in increased methylation of CDKN2B promoter] which results in decreased expression of CDKN2B mRNA | CTD | PMID:20044985 |
| benzene | decreases expression | ISO | RGD:1348731 | 6480464 | Benzene results in decreased expression of CDKN2B mRNA | CTD | PMID:20044985 |
| benzo[a]pyrene | increases expression | ISO | RGD:1348731 | 6480464 | Benzo(a)pyrene results in increased expression of CDKN2B mRNA | CTD | PMID:20064835 |
| benzo[a]pyrene | increases expression | ISO | RGD:731792 | 6480464 | Benzo(a)pyrene results in increased expression of CDKN2B mRNA | CTD | PMID:19770486 PMID:22228805 |
| benzo[a]pyrene | increases expression | ISO | RGD:1348731 | 6480464 | Benzo(a)pyrene results in increased expression of CDKN2B mRNA | CTD | PMID:21871943 PMID:20064835 |
| benzo[a]pyrene | increases expression | ISO | RGD:1348731 | 6480464 | Benzo(a)pyrene results in increased expression of CDKN2B mRNA | CTD | PMID:20064835 PMID:21871943 |
| benzo[a]pyrene | increases expression | ISO | RGD:731792 | 6480464 | Benzo(a)pyrene results in increased expression of CDKN2B mRNA | CTD | PMID:19770486 |
| bisphenol A | increases expression | ISO | RGD:731792 | 6480464 | bisphenol A results in increased expression of CDKN2B mRNA | CTD | PMID:21932408 |
| calciol | increases expression | ISO | RGD:731792 | 6480464 | Cholecalciferol results in increased expression of CDKN2B mRNA | CTD | PMID:16508948 |
| calcitriol | increases expression | ISO | RGD:1348731 | 6480464 | Calcitriol results in increased expression of CDKN2B mRNA | CTD | PMID:21592394 |
| calcitriol | multiple interactions | ISO | RGD:1348731 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of CDKN2B mRNA | CTD | PMID:21592394 |
| chromium(6+) | increases expression | EXP | | 6480464 | chromium hexavalent ion results in increased expression of CDKN2B protein | CTD | PMID:21621607 |
| coumestrol | multiple interactions | ISO | RGD:1348731 | 6480464 | [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN2B mRNA; more ... | CTD | PMID:19167446 |
| coumestrol | decreases expression | ISO | RGD:1348731 | 6480464 | Coumestrol results in decreased expression of CDKN2B mRNA | CTD | PMID:19167446 |
| cyclosporin A | increases expression | ISO | RGD:1348731 | 6480464 | Cyclosporine results in increased expression of CDKN2B mRNA | CTD | PMID:21632981 |
| daunorubicin | increases expression | ISO | RGD:1348731 | 6480464 | Daunorubicin results in increased expression of CDKN2B mRNA | CTD | PMID:12656675 |
| Delta(9)-tetrahydrocannabinol | increases expression | ISO | RGD:731792 | 6480464 | Tetrahydrocannabinol results in increased expression of CDKN2B mRNA | CTD | PMID:21542829 |
| diarsenic trioxide | decreases methylation | ISO | RGD:1348731 | 6480464 | arsenic trioxide results in decreased methylation of CDKN2B gene | CTD | PMID:12679007 PMID:17294728 |
| diarsenic trioxide | increases expression | ISO | RGD:1348731 | 6480464 | arsenic trioxide results in increased expression of CDKN2B mRNA | CTD | PMID:12679007 PMID:11877046 |
| diarsenic trioxide | multiple interactions | ISO | RGD:1348731 | 6480464 | [arsenic trioxide results in decreased methylation of CDKN2B promoter] which results in increased expression of CDKN2B mRNA | CTD | PMID:20596618 |
| diarsenic trioxide | increases expression | ISO | RGD:1348731 | 6480464 | arsenic trioxide results in increased expression of CDKN2B mRNA | CTD | PMID:11877046 PMID:12679007 |
| diarsenic trioxide | decreases methylation | ISO | RGD:1348731 | 6480464 | arsenic trioxide results in decreased methylation of CDKN2B gene | CTD | PMID:17294728 PMID:12679007 |
| diarsenic trioxide | multiple interactions | ISO | RGD:1348731 | 6480464 | [arsenic trioxide results in decreased methylation of CDKN2B promoter] which results in increased expression of CDKN2B mRNA | CTD | PMID:20596618 PMID:20596618 |
| dichlorine | multiple interactions | EXP | | 6480464 | [Ozone co-treated with Chlorine] results in decreased expression of CDKN2B mRNA | CTD | PMID:18636392 |
| dimethylarsinic acid | decreases expression | EXP | | 6480464 | Cacodylic Acid results in decreased expression of CDKN2B mRNA | CTD | PMID:17720352 |
| disodium selenite | increases expression | ISO | RGD:1348731 | 6480464 | Sodium Selenite results in increased expression of CDKN2B mRNA | CTD | PMID:16705456 |
| fluoxetine | increases expression | ISO | RGD:731792 | 6480464 | Fluoxetine results in increased expression of CDKN2B mRNA | CTD | PMID:21497159 |
| formaldehyde | increases expression | ISO | RGD:1348731 | 6480464 | Formaldehyde results in increased expression of CDKN2B mRNA | CTD | PMID:20655997 |
| formaldehyde | decreases expression | EXP | | 6480464 | Formaldehyde results in decreased expression of CDKN2B mRNA | CTD | PMID:12679049 |
| fumonisin B1 | increases expression | ISO | RGD:731792 | 6480464 | fumonisin B1 results in increased expression of CDKN2B mRNA | CTD | PMID:16221962 |
| furan | increases expression | EXP | | 6480464 | furan results in increased expression of CDKN2B mRNA | CTD | PMID:20562052 |
| furan | increases expression | EXP | | 6480464 | furan results in increased expression of CDKN2B mRNA | CTD | PMID:20562052 PMID:22079235 |
| gefitinib | increases expression | ISO | RGD:1348731 | 6480464 | gefitinib results in increased expression of CDKN2B mRNA; more ... | CTD | PMID:17513607 |
| hydrogen peroxide | decreases expression | ISO | RGD:1348731 | 6480464 | Hydrogen Peroxide results in decreased expression of CDKN2B mRNA | CTD | PMID:12419474 |
| hydrogen peroxide | decreases expression | ISO | RGD:731792 | 6480464 | Hydrogen Peroxide results in decreased expression of CDKN2B mRNA | CTD | PMID:14729362 |
| indole-3-methanol | increases expression | ISO | RGD:1348731 | 6480464 | indole-3-carbinol results in increased expression of CDKN2B | CTD | PMID:16082211 |
| linalool | increases expression | ISO | RGD:1348731 | 6480464 | linalool results in increased expression of CDKN2B mRNA | CTD | PMID:19922762 |
| methamphetamine | increases expression | EXP | | 6480464 | Methamphetamine results in increased expression of CDKN2B mRNA | CTD | PMID:15644446 |
| N-nitrosodiethylamine | decreases expression | ISO | RGD:731792 | 6480464 | Diethylnitrosamine results in decreased expression of CDKN2B mRNA | CTD | PMID:18691550 |
| N-nitrosodiethylamine | multiple interactions | EXP | | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA; more ... | CTD | PMID:21295105 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:731792 | 6480464 | IKBKB protein inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN2B mRNA] | CTD | PMID:18691550 |
| N-nitrosodimethylamine | increases expression | EXP | | 6480464 | Dimethylnitrosamine results in increased expression of CDKN2B mRNA | CTD | PMID:15138612 |
| ozone | multiple interactions | EXP | | 6480464 | [Ozone co-treated with Chlorine] results in decreased expression of CDKN2B mRNA | CTD | PMID:18636392 |
| pentachlorophenol | increases expression | EXP | | 6480464 | Pentachlorophenol results in increased expression of CDKN2B mRNA | CTD | PMID:19442831 |
| phorbol 13-acetate 12-myristate | multiple interactions | ISO | RGD:1348731 | 6480464 | 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of CDKN2B protein] | CTD | PMID:12421932 |
| pirinixic acid | multiple interactions | ISO | RGD:1348731 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CDKN2B mRNA | CTD | PMID:19710929 |
| pirinixic acid | multiple interactions | ISO | RGD:731792 | 6480464 | PPARA protein affects the reaction [pirinixic acid results in increased expression of CDKN2B mRNA] | CTD | PMID:16221962 |
| pirinixic acid | increases expression | ISO | RGD:731792 | 6480464 | pirinixic acid results in increased expression of CDKN2B mRNA | CTD | PMID:16221962 |
| pirinixic acid | decreases expression | ISO | RGD:731792 | 6480464 | pirinixic acid results in decreased expression of CDKN2B mRNA | CTD | PMID:17426115 |
| prednisone | increases expression | ISO | RGD:1348731 | 6480464 | Prednisone results in increased expression of CDKN2B protein | CTD | PMID:15034294 |
| quercetin | increases expression | ISO | RGD:1348731 | 6480464 | Quercetin results in increased expression of CDKN2B mRNA | CTD | PMID:21632981 |
| quercetin 3-O-beta-D-glucoside | multiple interactions | EXP | | 6480464 | isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] | CTD | PMID:21295105 |
| resveratrol | multiple interactions | ISO | RGD:1348731 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of CDKN2B mRNA | CTD | PMID:19167446 |
| rifampicin | multiple interactions | ISO | RGD:1348731 | 6480464 | [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA | CTD | PMID:21127053 |
| tert-butyl hydroperoxide | decreases expression | ISO | RGD:1348731 | 6480464 | tert-Butylhydroperoxide results in decreased expression of CDKN2B mRNA | CTD | PMID:12419474 |
| tert-butyl hydroperoxide | decreases expression | ISO | RGD:731792 | 6480464 | tert-Butylhydroperoxide results in decreased expression of CDKN2B mRNA | CTD | PMID:14729362 |
| testosterone | multiple interactions | ISO | RGD:1348731 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of CDKN2B mRNA | CTD | PMID:21592394 |
| testosterone | increases expression | ISO | RGD:1348731 | 6480464 | Testosterone results in increased expression of CDKN2B mRNA | CTD | PMID:21592394 |
| thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of CDKN2B mRNA | CTD | PMID:22659510 |
| trans-resveratrol | multiple interactions | ISO | RGD:1348731 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of CDKN2B mRNA | CTD | PMID:19167446 |
| trichostatin A | multiple interactions | ISO | RGD:1348731 | 6480464 | decitabine promotes the reaction [trichostatin A results in increased expression of CDKN2B mRNA] | CTD | PMID:18718068 |
| trichostatin A | increases expression | ISO | RGD:1348731 | 6480464 | trichostatin A results in increased expression of CDKN2B mRNA | CTD | PMID:18718068 |
| urethane | decreases expression | ISO | RGD:731792 | 6480464 | Urethane results in decreased expression of CDKN2B mRNA | CTD | PMID:12117781 |
| zinc dichloride | decreases expression | ISO | RGD:1348731 | 6480464 | zinc chloride results in decreased expression of CDKN2B mRNA | CTD | PMID:21540303 |